RxDoctor Payments Data

David Dunch, MD

Colon & Rectal Surgery · Youngstown, OHNPI 1457339376

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $490 and has fallen 88.8% since, to $55 in 2025.

$1,731in general payments, 2019–2025

Across 87 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$402
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$331
  • AbbVie$208
  • Braintree Laboratories, Inc.$190
  • Medtronic$133
  • Bristol Myers Squibb$91
  • plus $376 from 10 others

What the payments were for

  • Food & beverage$1,65796%
  • Gifts$734%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,731 in reported general payments places this provider in the 55th percentile of 101 colon & rectal surgery providers in Ohio.

See all colon & rectal surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$47,406
Medicare patients
223
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClenpiqSod Picosulf/Mag Ox/Citric Ac116$20,150
Mesalamine59$14,042
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$273
Hydrocortisone23$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$402$20,150116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 101 colon & rectal surgery providers in Ohio.

Other colon & rectal surgery in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →